Back to Rheumatology



Lupus Market Research

What is Lupus?

Lupus is a chronic autoimmune condition that causes a multitude of symptoms, attacking joints, skin, and internal organs in particular. Lupus strikes mostly women of childbearing age. However, men, children, and teenagers develop lupus, as well. Certain ethnic groups—including African American, Asian, Hispanic/Latino, and Native American—are at higher risk for developing lupus than the rest of the population. While the cause of lupus is unknown, medical experts presume it may manifest due to genetic predisposition, a response to hormones, or triggers such as: ultraviolet (UV) rays, infections, antibiotics, previous injuries, emotional stress, and more. While “lupus” is used as an all-encompassing term, there are various forms of lupus, including systemic lupus erythematosus (SLE), which makes up the bulk of all lupus cases, lupus nephritis (LN), where the immune system attacks the kidneys, and cutaneous lupus erythematosus (CLE), where the immune system affects the skin.  As many as half of the SLE patients may develop LN, which can cause serious and sometimes fatal complications, such as kidney failure, in which a patient may be put on dialysis or need a kidney transplant.

Spherix Global Insights – Rheumatology – Lupus

Spherix Global Insights’ rheumatology therapeutic team is a leading provider of independent syndicated lupus market research, insights, business intelligence & advisory services.

This year, Spherix’s rheumatology team is publishing nine (9) studies covering lupus including:

  • RealTime Dynamix™: Lupus Nephritis (US)
  • RealTime Dynamix™: Systemic Lupus Erythematosus (US)
  • RealTime Dynamix™: Systemic Lupus Erythematosus (EU)
  • Launch Dynamix™: Saphnelo (AstraZeneca) in Systemic Lupus Erythematosus (US)
  • Patient Chart Dynamix™: Lupus Nephritis (US)
  • Patient Chart Dynamix™: Moderate to Severe Systemic Lupus Erythematosus (US)
  • Patient Chart Dynamix™: Moderate to Severe Systemic Lupus Erythematosus (EU)
  • Market Dynamix™: Cutaneous Lupus Erythematosus (CLE)
  • Special Topix™: Patient Dynamics in Systemic Lupus Erythematosus (US)

Spherix’s RealTime Dynamixservice includes quarterly or semiannual reports, respectively in the US and EU, providing an unbiased view of the competitive landscape within the lupus market.

Spherix’s Launch Dynamixservice consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide monthly benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports covering promotional activity, barriers to uptake, and patient types being identified for the launch brand.

Spherix’s Patient Chart Dynamixservice includes patient level data detailing clinical and non-clinical patient demographics, along with rationale for treatment choices. It reveals real patient management patterns through rigorous analysis of large-scale patient chart audits.

Spherix’s Market Dynamixservice includes analysis of markets anticipated to experience a paradigm shift within the next three to five years. Its insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

Spherix’s Special Topixservice includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.

Follow Spherix Rheumatology on Social Media


For Guests & Current Clients

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:


Get more information on Lupus Coverage